What Ultrafen (Ibuprofen) Treats: Main Uses and Benefits

Ultrafen is commonly used due to its ability to provide symptomatic support across key areas of physical discomfort and illness. It is generally applied in contexts where short-term, supportive relief from acute symptoms is needed.

Symptom-Focused Relief

Ultrafen is commonly used to help with symptoms related to physical discomfort, which helps to ease the overall burden of symptoms such as headaches, toothaches, muscle aches, and menstrual cramps. It is relevant for easing symptoms related to inflammatory or irritative states, including localized swelling, tenderness, and stiffness, and is commonly used to help manage fever and accompanying body aches associated with acute episodes like the common cold or flu.

Therapeutic Benefit

The medication is relevant in contexts marked by increased discomfort, as it may assist with helping patients cope more steadily with symptom fluctuations and supporting functional stability during periods of temporary strain. It is applied when conditions produce significant symptomatic burden, such as with minor sprains or the recurring manifestations of arthritis.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility and Contraindication Status

Official regulatory documents define strict criteria for the use of Ultrafen (ibuprofen). The medicine is contraindicated (must not be used) in several specific patient populations due to the risk of serious adverse events.

Populations for Whom Use is Contraindicated

• Individuals with a known hypersensitivity or allergic-type reaction (e.g., asthma, urticaria, severe rash) to ibuprofen, aspirin, or any other Nonsteroidal Anti-inflammatory Drug (NSAID).
• Patients with active or history of recurrent gastrointestinal bleeding, perforation, or peptic ulcer disease.
• Individuals with severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure.
• Patients right before or immediately after Coronary Artery Bypass Graft (CABG) surgery.
• Women in the last trimester of pregnancy (typically from 30 weeks of gestation).

Age and Condition-Specific Restrictions

Ibuprofen is generally not recommended for use in children under 6 months of age, as safety and efficacy have not been established in this age group, and physician consultation is required. Elderly patients and those with pre-existing conditions like uncontrolled hypertension, mild-to-moderate renal or hepatic impairment, or established cardiovascular disease should use the medicine with caution, often necessitating the lowest effective dose for the shortest duration possible, as advised in official labeling.

Interactions with other medicines and products — official regulatory information for Ultrafen (ibuprofen)

This regulatory profile outlines interactions documented in official government labeling (FDA, EMA, TGA) that impose specific constraints on co-administration with other substances.

Interaction Scope

Interaction Classifications (High-Level)

Resulting Interaction Structure

The regulatory documents formally define the Ibuprofen interaction structure around pharmacodynamic risk amplification and pharmacokinetic interference. This leads to mandatory restrictions, including contraindicated combinations with other NSAIDs and the requirement for timing separation from low-dose Aspirin to preserve its anti-platelet effect. Ibuprofen also reduces the clearance of Lithium and Methotrexate, resulting in officially documented increased plasma concentrations of those medicines.

Ultrafen (Ibuprofen) functions as a non-selective, reversible inhibitor of the Cyclooxygenase ( COX-1 and COX-2) enzymes. This molecular action immediately suppresses the chemical cascade that converts arachidonic acid into prostaglandins ( PGE2), which are key physiological mediators. This direct blockade of synthesis is the core mechanism that initiates all subsequent physiological consequences. . The reduction in PGE2 concentration exerts a dual regulatory effect on both the central and peripheral nervous systems. Peripherally, it dampens the chemical sensitization of nociceptors (pain-sensing nerves), leading to decreased chemical sensitization of afferent nerve endings. Centrally, it acts within the hypothalamus to prevent PGE2 from raising the body's internal temperature set point, and supports the resetting of the elevated temperature set point. The mechanism is intrinsically linked to processes that rely on PGE2 for propagation, meaning it does not operate against signaling mediated by other biological pathways. Furthermore, non-selective inhibition affects COX-1, which generates prostaglandins that maintain certain basal physiological processes, defining a boundary on the drug's selectivity.

Ultrafen, which contains the active substance ibuprofen, is administered according to standardized protocols. The medicine is approved for two systemic routes of administration: oral (using tablets, capsules, or suspension) and intravenous (IV) injection, which is typically used in a supervised clinical setting.

Usage is governed by the principle of administering the lowest effective dose for the shortest duration necessary. For adult use, dosing schedules are based on the intended use and prescription status. Non-prescription (OTC) use involves doses of 200 mg to 400 mg per administration, with a maximum total daily intake of 1200 mg. Higher doses, up to 800 mg per dose, are prescribed for inflammatory conditions, where the maximum daily dose may be increased up to 3200 mg. Administrations are generally separated by a minimum of 4 to 6 hours.

Specific administration instructions vary by formulation. Oral products are often recommended to be taken with food or milk to help mitigate gastrointestinal discomfort. Intravenous administration requires careful preparation, including the mandated dilution of the solution before it is infused slowly over a minimum of 30 minutes for adult patients. For special populations, pediatric dosing is calculated based on body weight, and in older adults, the lowest possible dosage should be utilized.

Research evidence / Overview of studies for Ultrafen (ibuprofen)

Evidence for Use in Acute Symptomatic Pain

Research used in studies exploring how symptoms change over time has focused heavily on the study of outcomes related to physical discomfort, such as mild to moderate pain from headaches, dental procedures, and minor musculoskeletal injuries. A significant component of the evidence base consists of short-term, randomized controlled trials (RCTs). In these studies, researchers monitored changes in patient-reported outcomes describing perceived discomfort, often using pain intensity scales. Studies monitored both the intensity of the pain and the time until patients requested further pain medication. Research provides context but not individual predictions.

Evidence for Fever Reduction (Antipyresis)

The structure of the research dedicated to elevated body temperature involves randomized controlled trials (RCTs) and systematic reviews that focus on outcomes related to systemic or functional imbalance. Studies primarily monitored physiological strain or stress by measuring the absolute change in body temperature over defined time intervals. This research was studied for pediatric patient groups—children experiencing temporary physiological imbalance.

While research has examined this area, certainty remains low regarding definitive comparisons to all other agents across every measurable time point. The evidence quality varies across studies due to differences in how fever was defined and measured.

Evidence for Symptomatic Management of Inflammatory States

Research was evaluated in studies exploring how symptoms change over time for conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis and menstrual cramps (dysmenorrhea). The available evidence includes intermediate-term RCTs and aggregated data from network meta-analyses of the NSAID drug class. Studies monitored outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort over the study period. There is limited information for long-term outcomes for typical, sporadic over-the-counter use, as results apply only to the populations studied in the original trials.

What Remains Unaddressed or Uncertain in the Research

The overall evidence landscape is designed to address episodic or acute changes, meaning that follow-up durations were limited to ultra-short (hours) or short-term periods (one day) in the majority of clinical trials for common uses. One key limitation is that comparative evidence is lacking across all available formulations (e.g., standard tablet, liquid gel cap, suspension) to explore the differences in time to onset and peak effect. The current research base provides limited information regarding whether long-term use for chronic pain conditions can be reliably extrapolated from the acute, short-term data set.

Key Studies & References

1. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review
2. Ibuprofen - StatPearls - NCBI Bookshelf (Used for OA/chronic indications background)
3. FDA Label: IBUPROFEN Tablets, 200 mg (Drug Facts Label)
4. Analgesia guidelines for acute pain management in adults (NHS Scotland)

Common questions about Ultrafen (ibuprofen) (FAQ)

Q: What is the main difference between Ultrafen and naproxen?

Both Ultrafen (ibuprofen) and naproxen belong to the class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and function through similar mechanisms. Regulatory documents state a key difference is their duration of action. Ibuprofen is generally described as short-acting, with effects supporting a dosing interval of 4 to 6 hours. Naproxen, in contrast, is described as long-acting.

Q: Why is Ultrafen sometimes sold under different names?

Ultrafen is one of many trade names used by different companies for products containing the active ingredient ibuprofen. Regulatory documents clarify that a medicine may be sold under a unique brand name or simply under its generic name, ibuprofen. All forms contain the same core active substance.

Q: What are the most common reasons someone might stop using Ultrafen?

Regulatory documents state that use should be discontinued, and a healthcare professional should be contacted if certain safety signals are observed. These signals include symptoms worsening, new symptoms developing, or if relief is not achieved within the time frames specified for over-the-counter use (e.g., 10 days for pain or 3 days for fever).

Q: Why is there a specific maximum amount of Ultrafen allowed per day?

Regulatory bodies set maximum daily limits on all medicines to ensure they are used appropriately. The limits are established to govern safe use and help mitigate the risk of serious side effects, particularly those affecting the gastrointestinal system.

Q: Are there any known interactions between Ultrafen and caffeine?

Regulatory documents listing official drug interactions do not universally name caffeine as a substance that significantly alters the action of ibuprofen. However, some product information discusses the existence of fixed-dose combinations where caffeine is intentionally included with ibuprofen in a single product.

Q: How does Ultrafen differ from paracetamol (acetaminophen)?

Official health authority information highlights a key difference between these two common pain relievers. Ultrafen is a Nonsteroidal Anti-inflammatory Drug (NSAID) that reduces pain, fever, and inflammation by inhibiting COX enzymes. Paracetamol (acetaminophen) primarily reduces pain and fever but does not treat inflammation through the same mechanism.

Q: Is there a certain time of day that is better for taking Ultrafen?

Official guidance indicates that ibuprofen is taken as needed for symptoms, and there is no specific time of day that is inherently better. Regulatory labeling frequently notes that the medicine is typically taken with or after food to reduce the potential for stomach upset, and that doses are separated by a minimum required time.

Q: What happens if a person misses a dose of Ultrafen?

Since the medicine is typically used when symptoms occur, regulatory information notes that a dose may be skipped if it is almost time for the next dose. Official recommendations state that two doses should not be used at the same time.

Q: Does Ultrafen cause any changes in mood or behavior?

Official product documents list certain central nervous system effects as possible side effects, such as dizziness and nervousness. A specific adverse event involving mood or behavioral changes is not listed among the common side effects in authoritative sources.

Q: How quickly is Ultrafen eliminated from the body?

Pharmacokinetic data from regulatory summaries describes how the drug moves through the body. The elimination half-life—a measure of how quickly the body clears the substance—is consistently reported to be around 1.8 to 2.2 hours in healthy adults.

Q: What are the official recommendations for stopping Ultrafen use?

Official documents describe that immediate discontinuation of use is indicated if serious symptoms—such as chest pain, trouble breathing, or signs of gastrointestinal bleeding—are experienced. For non-serious issues, use should stop if the condition worsens or persists beyond the recommended short-term duration.

Q: What is the typical duration of effect for a dose of Ultrafen?

Regulatory dosing instructions suggest that the effects generally last long enough to support a dosing interval of 4 to 6 hours for most over-the-counter uses. The effects generally last long enough to support the mandated dosing interval.

Q: Does Ultrafen cause sleepiness or drowsiness?

Drowsiness is listed in some official product information as a potential side effect. Official product information contains warnings that caution should be exercised with activities like driving or operating machinery if drowsiness occurs.

Q: Can Ultrafen be used for all types of body pain?

Official indications describe the medicine as approved for the temporary relief of mild to moderate pain associated with various common conditions. These include symptoms like headache, toothache, and minor musculoskeletal injuries, as detailed in the regulatory indications for use.

Q: What is the relationship between Ultrafen and blood pressure?

Warnings in official labeling indicate that Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may be associated with the development of new or worsening high blood pressure (hypertension). Due to this relationship, monitoring of blood pressure is a caution noted in official documents.

Q: What is the maximum number of consecutive days Ultrafen is typically recommended for non-prescription use?

Over-the-counter product information generally specifies a maximum duration of use to guide self-treatment. This limit is often set at 10 days for pain relief or 3 days for fever reduction, unless a healthcare professional advises otherwise.

How to Store and Dispose of Ultrafen (Ibuprofen)

Official regulatory information mandates specific conditions to ensure product stability and safety. Ultrafen (ibuprofen) must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and shielded from excessive heat (above 40 C) and moisture. Liquid forms of the medication must not be allowed to freeze. The product must be kept in its original, tightly closed container and stored out of the reach and sight of children, with safety caps always locked.

For disposal, the product should not be flushed down the toilet. The required protocol prioritizes using a medicine take-back program. If a take-back option is unavailable, the unneeded medicine should be mixed with an unpalatable substance, sealed in a bag, and discarded in the household trash.